Publications by authors named "Soichi Iwanaka"
Article Synopsis
- Epidermal growth factor receptor (EGFR)-mutated squamous cell carcinoma (SCC) is rare compared to adenocarcinoma, and the effectiveness of osimertinib, a treatment known to work for adenocarcinoma, is uncertain for SCC.
- An 83-year-old male with EGFR exon19 deletion SCC treated with osimertinib experienced disease progression after 18 days, leading to his death three weeks later.
- Autopsy and next-generation sequencing indicated the presence of other genetic mutations (TP53 R158L, CDK6, and KRAS amplifications), suggesting these could explain osimertinib's failure in his case.
Reports on the efficacy of second-line treatment with cytotoxic agents after treatment with immune checkpoint inhibitors are limited. Here, we retrospectively evaluated patients in the real-world clinical practice treated with docetaxel or docetaxel plus ramucirumab. Ninety-three patients treated with docetaxel or docetaxel plus ramucirumab as a second- or later-line therapy were included.
View Article and Find Full Text PDFArticle Synopsis
- - Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction that makes bronchial asthma worse, and dupilumab has shown potential to reduce the need for glucocorticoids in patients with this condition.
- - A 54-year-old woman diagnosed with ABPA experienced multiple asthma exacerbations and underwent glucocorticoid treatment, alongside itraconazole, but eventually transitioned to treatment with dupilumab.
- - Remarkably, this case reports the first instance where a patient with ABPA was able to completely stop using glucocorticoids after starting dupilumab treatment.
Article Synopsis
- The study investigates the effectiveness of second-line treatments for non-small cell lung cancer (NSCLC) patients with T790M-negative mutations or unknown causes of resistance after initial tyrosine kinase inhibitor (TKI) therapy.
- A total of 39 patients were treated with either chemotherapy (28 patients) or second-generation TKIs (11 patients) after the first-line therapy, with median progression-free survival (PFS) and overall survival (OS) measured for both groups.
- Results indicate no significant differences in PFS (5.4 months for chemotherapy vs. 3.4 months for TKIs) or OS (16.1 months for chemotherapy vs. 12.8 months for TKIs), suggesting that TKIs
Calcification in lung nodules usually indicates a benign lesion. Here, we report the case of a 59-year-old male patient with a well defined 30 mm calcified nodule in his right upper lung lobe and calcified mediastinal lymph nodes. The mass was diagnosed as adenocarcinoma by transbronchial biopsy.
View Article and Find Full Text PDF